INSM

Insmed Incorporated

27.92 USD
-0.11 (-0.39%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Insmed Incorporated stock is down -3.62% since 30 days ago. The next earnings date is May 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 23 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 2 PUTs, 8 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 Feb 17:33 20 Dec, 2024 17.50 PUT 85 86
23 Feb 14:39 19 Jul, 2024 40.00 CALL 45 898
23 Feb 14:39 19 Jul, 2024 40.00 CALL 90 898
23 Feb 14:39 19 Jul, 2024 40.00 CALL 47 898
23 Feb 14:48 16 Aug, 2024 45.00 CALL 83 111
26 Feb 18:54 19 Jul, 2024 35.00 CALL 56 1485
26 Feb 18:54 19 Jul, 2024 35.00 CALL 42 1485
26 Feb 18:55 19 Jul, 2024 35.00 CALL 77 1485
28 Feb 14:46 19 Jul, 2024 30.00 CALL 50 3759
29 Feb 14:52 19 Jul, 2024 20.00 PUT 49 20800

About Insmed Incorporated

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1.

  • Guggenheim
    Tue Feb 27, 12:10
    buy
    confirm
  • UBS
    Tue Feb 27, 05:37
    buy
    initial
  • Wolfe Research
    Thu Feb 15, 06:22
    buy
    initial